On May 14, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2025 that ended March 31, 2025 and provided a business update. The company has initiated outreach to potential investigators along with manufacturing-related activities to support U.S. regulatory approval for a Phase 2 study of EB06 in the treatment of vitiligo. Manufacturing of EB06 is likely to be finished in the second half of 2025 such that the company can submit the manufacturing data to the FDA as part of the Investigational New Drug (IND) application. Once cleared by the FDA, topline results could be available in approximately 12-18 months.
